SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 725.62+3.0%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Felix B who wrote (2337)3/10/2018 10:37:47 AM
From: Miljenko Zuanic1 Recommendation

Recommended By
Biotech Jim

  Read Replies (1) of 3559
 
Regeneron achieved modest victory with Odyssey:

globenewswire.com

and with new ICER calculation on cost effectiveness, opportunity to penetrate market:

icer-review.org

It was clear for long time that absolute reduction in the LDLc (and other lipids associated with CV diseases) is what count, and >60 mg/dL reduction for high risk subjects and with LDLc>100/120 is BENEFICIAL, regardless (and/or on top) of statin and other lipid lowering therapy. ODYSSEY confirmed this and maybe HC community will start to act accordingly.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News